evipedia.aidev
← Back

Salidroside for Health & Longevity

Evidence Review created on 08/14/2026 using AI4L / Grok 4.5

Also known as: Rhodioloside, Tyrosol glucoside, 2-(4-Hydroxyphenyl)ethyl β-D-glucopyranoside

Motivation

Salidroside is a single plant phenol found mainly in the roots of Rhodiola rosea and related high-altitude species. Traditional systems used the whole root as an adaptogen—an agent thought to raise resistance to physical and mental strain. Isolated salidroside is now sold on its own and made by fermentation as well as extracted from plants. Longevity-minded adults are interested because laboratory work links it to energy-sensing pathways and longer life in simple organisms.

Most human trials still use whole-root extracts that also contain other Rhodiola root compounds. One recent trial of purified salidroside in active young adults reported better oxygen use during high-intensity intervals and a smaller rise in a muscle-damage marker. Safety work on a bioengineered form did not find DNA-damaging activity, and high doses in rats did not produce harm.

This review examines isolated salidroside for health and longevity. It separates evidence on the pure compound from evidence on mixed Rhodiola extracts, and it sets out benefits, risks, practical use, and quality issues.

Benefits - Risks - Protocol - Conclusion

High-level overviews that introduce salidroside itself or the Rhodiola rosea adaptogen class it comes from.

No dedicated salidroside or Rhodiola piece by Peter Attia or Lifespan.io was found. FoundMyFitness search returned only guest mentions of Rhodiola rosea, not a Rhonda Patrick monograph. Chris Kresser mentions Rhodiola only in passing.

Grokipedia

  • Salidroside

    Fact-checked Grokipedia entry covering chemistry, traditional use, biosynthesis, pharmacology, and the still-limited clinical translation of isolated salidroside.

Examine

  • Salidrosides

    Examine’s isolated-compound page, last updated 28 Aug 2025, linking salidroside to brain-health claims and flagging that human trials remain sparse.

ConsumerLab

No dedicated ConsumerLab article for isolated salidroside was found as of 14 August 2026. ConsumerLab’s Rhodiola rosea review tests salidroside content in commercial extracts.

Systematic Reviews

Preclinical meta-analyses of isolated salidroside plus the main human systematic reviews of Rhodiola rosea extracts, which contain salidroside plus other actives.

No systematic review of isolated-salidroside human adverse events was found; safety is unrepresented at that level.

Mechanism of Action

Salidroside is a phenylethanoid glycoside (a sugar-linked plant phenol): glucose bound to tyrosol. Gut enzymes can split the pair, and tyrosol often reaches tissues more readily than the parent molecule.

Several pathways are proposed. It can switch on AMP-activated protein kinase (AMPK, a cellular fuel sensor that responds to energy stress); mouse liver work using this route reduced fat buildup and inflammation. It can also turn on Nrf2 (nuclear factor erythroid 2–related factor 2, a transcription factor that raises antioxidant enzymes such as superoxide dismutase) and damp NF-κB (nuclear factor kappa B, a switch that drives inflammatory cytokines). In low-oxygen models it engages HIF-1α (hypoxia-inducible factor 1-alpha, the main hypoxia-response program) and SIRT1 (sirtuin 1, an NAD-dependent deacetylase—NAD is nicotinamide adenine dinucleotide, a cellular redox cofactor—tied to mitochondrial quality). Separate work finds direct binding to HSP90 (heat shock protein 90, a stress-response chaperone), with longer life in invertebrate models.

A competing view is that many human “Rhodiola” effects come from the whole-root mix (rosavins plus salidroside), so the isolated compound may not reproduce every extract finding. Pharmacologically it is multi-target rather than a single-receptor ligand. Gut and tissue β-glucosidases (sugar-splitting enzymes) can hydrolyze it to tyrosol; the parent is not a major cytochrome P450 substrate. Intravenous half-life in rats is about one hour, kidney clearance dominates, tissue levels stay below plasma, and brain entry of the parent is limited. Predicted human plasma after 60 mg by mouth is under 2 micromolar.

Historical Context & Evolution

Rhodiola rosea roots were used for fatigue, cold, and altitude strain in Siberian, Scandinavian, and Tibetan practice; Chinese medicine lists the plant as Hong Jing Tian. Soviet programs in the 1960s treated the root as an adaptogen for soldiers, athletes, and workers. In 1967, Troshchenko and Kutikova isolated the tyrosol glucoside and named it rhodioloside—today’s salidroside.

Early swimming and stress tests in animals attributed anti-fatigue effects to extracts standardized for this compound. Human research then clustered around proprietary root extracts (SHR-5, WS 1375), not the pure molecule. Those trials, from the 2000s onward, reported mixed help for exam stress, burnout, and mild depression, and they remain the main clinical record.

Two later shifts matter. First, wild Rhodiola is slow-growing and often adulterated, so chemists and synthetic biologists now make nature-identical salidroside by fermentation. Second, cell and animal papers have recast the compound as a candidate longevity molecule—via AMPK, Nrf2, and HSP90—rather than only a traditional stimulant. That laboratory case is broad; the isolated-compound human case is still a single short exercise trial plus a planned fertility study.

Expected Benefits

Benefits below are graded for isolated salidroside. Rhodiola rosea extract trials are used only as context, because those products also contain rosavins.

Low 🟩

High-intensity exercise oxygen use and muscle-damage markers

One DoubleRainbow Biosciences– and Lesaffre-funded RCT in 50 young adults used 60 mg/day for 16 days (Schwarz et al., 2024). Via AMPK-linked oxygen use, salidroside held higher percent predicted oxygen uptake in high-intensity intervals and avoided the placebo myoglobin (a muscle-damage protein) rise. It is a single short trial.

Magnitude: Isolated 60 mg/day for 16 days raised overall percent predicted oxygen uptake to 82.7% versus 79.6% on placebo; placebo, not salidroside, raised serum myoglobin 24 hours after exercise.

Speculative 🟨

Mental fatigue under load ⚠️ Conflicted

SHR-5 improved burnout in some extract trials (Olsson et al., 2009); others did not, with high or unclear bias (Ishaque et al., 2012). Isolated salidroside has no fatigue trial.

Mild depressive symptoms ⚠️ Conflicted

One SHR-5 RCT lowered depression scores versus placebo (Darbinyan et al., 2007); a later small three-arm extract-versus-sertraline trial in major depression was not significant (Mao et al., 2015). Isolated salidroside has no mood trial.

Lifespan and cellular aging programs

Salidroside bound HSP90 and extended invertebrate life. Rhodiola extracts lengthened fruit-fly life in University of California, Irvine work (Schriner et al., 2013). No human longevity trial exists; the basis is mechanistic and animal only.

Neuroprotection in Alzheimer-type models

A preclinical meta-analysis of 20 rodent Alzheimer studies found better behavior plus lower amyloid-β, oxidative stress, and inflammatory cytokines (Zhang et al., 2023). Human cognitive trials of isolated salidroside have not been published.

Cardiometabolic and fatty-liver effects

Rodent meta-analyses (Li et al., 2026) and an AMPK NASH (fatty liver with inflammation) study (Hu et al., 2021) report less liver fat and lower glucose. Human isolated-salidroside metabolic trials are absent.

Tumor-cell suppression in laboratory models

A 2026 systematic review of 47 preclinical papers described slower tumor growth and more programmed or iron-dependent cell death (Chu et al., 2026). This is cell and animal work only.

Benefit-Modifying Factors

  • Genetics: No polymorphism is established for salidroside response. Absorption may share sodium-dependent glucose transporters, so transporter variants are a theoretical modifier only.

  • Baseline biomarkers: Extract anti-fatigue signals clustered under exam or burnout load, often with a higher awakening cortisol. Isolated 60 mg exercise data come from already-fit young adults, not from high fasting-glucose or low fitness-marker groups.

  • Sex: The isolated 60 mg trial enrolled 30 men and 20 women and did not publish a sex-stratified effect. Dedicated sex-difference trials do not exist.

  • Health conditions: Preclinical AMPK and Nrf2 effects are larger in metabolic-stress models (fatty liver, diabetic kidney). Human confirmation is missing. Autoimmune and bipolar histories change the risk side more than the benefit side.

  • Age: Isolated human data stop at young adults. Older users have more hypotension, glucose-drug, and polypharmacy overlap; ovarian-aging work remains preclinical plus one unstarted in vitro fertilization (IVF) trial.

Potential Risks & Side Effects

Isolated salidroside has a thin human safety file. Most clinical adverse-event rates come from Rhodiola rosea extracts.

Low 🟥

Stimulant-type adverse events

Extract trials report mild dizziness, dry mouth, headache, nausea, insomnia, and irritability (Edwards et al., 2012). A 12-week RCT found adverse events in 30% on Rhodiola versus 17% on placebo. Isolated 60 mg/16-day use had no distinct harm signal.

Magnitude: Extract adverse-event rates around 30% in one 12-week RCT (Mao et al., 2015), mostly mild; isolated 60 mg/day for 16 days had no comparable signal. Rat NOAEL (no-observed-adverse-effect level, the highest dose without detected harm) was at least 2,000 mg/kg/day (Kasprzyk et al., 2022).

Blood-pressure lowering

Extract use is cautioned when blood pressure is already low, and dizziness is a reported event (Edwards et al., 2012). Isolated salidroside has no blood-pressure RCT. The plausible direction is an additive drop.

Magnitude: Not quantified in available studies. No isolated-salidroside blood-pressure trial reports a mmHg change; the caution is carried over from extract use and class effects.

Wrong-species or under-dosed extract as the “salidroside” source

About one fifth of commercial R. rosea products lacked rosavin, and many looked like other species (Booker et al., 2016). ConsumerLab has also found products below labeled marker levels. Unlabeled extracts are therefore a weak salidroside source.

Magnitude: About 20% of tested commercial R. rosea products lacked the species marker rosavin; additional products were low in claimed markers.

Speculative 🟨

Immune over-activation

Extracts can stimulate aspects of immunity in animals. People with active autoimmunity sometimes avoid adaptogens on that mechanistic basis. Isolated salidroside has no autoimmune outcome trial; the concern is theoretical.

Mood switching on the bipolar spectrum

Isolated case-level concern exists for stimulating botanicals in bipolar disorder. Isolated salidroside has not been studied in that population.

Risk-Modifying Factors

  • Genetics: Isolated salidroside did not inhibit major CYP enzymes (cytochrome P450 drug-metabolizers), MAO-A/B (monoamine oxidase), or OATP liver uptake transporters at expected 60 mg plasma levels. Extract interaction risk is not the same.

  • Baseline blood pressure and glucose: Starting hypotension or glucose-lowering drugs raises the chance of an additive drop. Isolated human magnitudes are unknown.

  • Sex: No sex-specific adverse-event split is published for isolated salidroside. Extract trials enrolled both sexes without a consistent sex-risk signal.

  • Health conditions: Bipolar spectrum, active autoimmunity, and treated diabetes or hypotension are the main theoretical high-risk groups. Pregnancy and lactation lack isolated-compound safety data.

  • Age: Older adults more often combine antihypertensives, glucose drugs, and sleep fragility; late-day dosing is the practical sleep risk.

Key Interactions & Contraindications

  • CYP substrates (simvastatin, midazolam, amlodipine): Isolated salidroside showed no meaningful CYP inhibition or induction at expected 60 mg levels (Kasprzyk et al., 2023) (caution). Whole extracts may still differ.

  • MAO-inhibitor antidepressants (phenelzine, tranylcypromine) and some SSRIs (selective serotonin reuptake inhibitors; sertraline, fluoxetine): Isolated salidroside did not inhibit MAO-A or MAO-B in vitro. Mood and blood pressure are the usual monitoring pair (caution).

  • Antihypertensives (lisinopril, amlodipine, hydrochlorothiazide) and other blood-pressure-lowering supplements (ashwagandha, magnesium, coenzyme Q10): Possible additive hypotension (caution). Typical practice is separate starts and seated blood-pressure logs.

  • Glucose-lowering drugs (metformin, SGLT2 (sodium-glucose cotransporter-2) inhibitors such as empagliflozin, insulin) and berberine: Possible extra glucose-lowering (monitor). Fasting glucose is the usual tracking marker.

  • Stimulants and late caffeine: Additive insomnia or irritability (caution). Morning dosing is the usual way to limit that overlap.

  • Over-the-counter decongestants (pseudoephedrine, phenylephrine) and sleep aids (diphenhydramine, doxylamine): Possible extra stimulation or extra sedation (caution). Morning dosing and holding nighttime antihistamine sleep aids is the usual separation.

  • Other adaptogens (ashwagandha, ginseng, eleuthero): Overlapping blood-pressure and immune effects (caution). ConsumerLab notes blood-pressure overlap and advises monitoring if Rhodiola is paired with ashwagandha.

Populations who should avoid salidroside:

  • Pregnancy and lactation (no adequate isolated-compound human data)
  • Bipolar I or a recent manic episode
  • Active autoimmune flare (theoretical immune stimulation)
  • Symptomatic hypotension or recent unstable coronary syndrome
  • Children (no isolated-compound pediatric data)

Risk Mitigation Strategies

  • Labeled isolated dose: Products that state milligrams of salidroside, not only “Rhodiola extract,” reduce wrong-species and under-dosed capsules.

  • Morning timing: Typical use is with breakfast or 30–60 minutes before training, not at night, which limits insomnia and irritability.

  • Low start if pressure or glucose runs low: Protocols often begin at 30 mg isolated or a low extract dose for one week, with seated blood-pressure and fasting-glucose logs, to limit additive hypotension and extra glucose-lowering.

  • One change at a time: Adding a single blood-pressure- or glucose-lowering agent, and holding extra adaptogens for two weeks, limits misattribution of hypotension, extra glucose-lowering, or stimulant-type events.

  • Stop rule for agitation: Agitation, reduced sleep need, or racing thoughts—especially with a bipolar history—are usual reasons to stop.

  • Short first block: A 2–4 week block, then reassessment of sleep, mood, and resting pressure, is the common first course to catch stimulant-type events and additive hypotension.

Therapeutic Protocol

  • Isolated compound (one published human regimen): 60 mg/day for 16 days in active young adults, split as 30 mg morning and 30 mg afternoon, using bioengineered, nature-identical salidroside.

  • Extract as a salidroside source: Common R. rosea capsules are 200–600 mg/day standardized to about 3% rosavins and 1% salidroside (roughly 2–6 mg salidroside), often split.

  • Competing approaches: Swedish Herbal Institute SHR-5 (340–680 mg extract; Panossian) for stress-fatigue versus DoubleRainbow isolated 60 mg (Schwarz) for exercise work. Neither is a default.

  • Time of day: Morning, or 30–60 minutes before hard training. Evening use is the period associated with sleep disruption.

  • Half-life and splitting: Human plasma half-life is about 0.5–2 hours, with an oral peak near 2 hours. Isolated human work split 60 mg into two 30 mg doses at least six hours apart; extracts are often split.

  • Genetics: No validated pharmacogenetic dose rule. Theoretical glucose-transporter overlap is not used to set milligrams.

  • Sex: No sex-specific isolated dose. The 60 mg trial mixed men and women.

  • Age: Isolated data are from ~21-year-olds. Older users more often start at the low end because of pressure and drug load.

  • Baseline markers: High residual fatigue or a high awakening cortisol is the extract use-case; isolated 60 mg was studied in trained adults, not in people with low fasting glucose or low seated pressure.

  • Health conditions: Pregnancy, mania, and autoimmune flare are usual exclusion settings. Treated hypotension or diabetes is paired with closer glucose and pressure logs.

Discontinuation & Cycling

  • Duration intent: Isolated salidroside has been studied for days to weeks, not as a proven lifelong longevity drug.

  • Withdrawal: No withdrawal syndrome is described for isolated salidroside or standard Rhodiola courses.

  • Taper: No taper is established. A same-day stop is the usual pattern after a short block.

  • Cycling: Some adaptogen clinics use 5 days on / 2 off or 8–12 weeks on / 2–4 off. Isolated salidroside has no cycling RCT.

  • After a stop: Sleep, resting pressure, and perceived effort are the practical washout signals over several days, given the short half-life.

Sourcing and Quality

  • Form: Isolated salidroside (extract or bioengineered) states milligrams of the compound. Rhodiola extracts should name species R. rosea and both 3% rosavins and 1% salidroside.

  • Identity testing: Third-party HPLC (high-performance liquid chromatography) for salidroside, and rosavin if an extract. Booker et al. found frequent species substitution and missing markers.

  • Biosynthetic option: Nature-identical salidroside from engineered Escherichia coli fermentation has published toxicology (NOAEL ≥2,000 mg/kg/day) and a completed human exercise RCT.

  • Extract brands: ConsumerLab has tested Thorne, Gaia, Solgar, and others for marker content; two products in its set missed labeled or expected amounts.

  • Conservation: Wild Rhodiola is slow-growing and over-harvested. Isolated or cultivated sources avoid that pressure.

Practical Considerations

  • Time to effect: Acute Rhodiola extract work often doses 60 minutes pre-exercise. Isolated 60 mg showed interval and myoglobin differences over a 16-day block, not a single dose.

  • Common pitfalls: Buying unlabeled “golden root”; assuming 3 mg of extract-salidroside equals 60 mg isolated; dosing at night; combining several adaptogens and attributing events to one agent.

  • Regulatory status: Isolated salidroside and Rhodiola extracts are dietary supplements in the United States, not FDA-approved drugs for any disease.

  • Cost and access: Standardized extracts are widely sold. Isolated biosynthetic salidroside usually costs more per milligram. Neither form is a typical insurer or national-health-system benefit, so payers have no systematic incentive to favor one.

Interaction with Foundational Habits

  • Sleep: Direct, possibly disrupting if dosed late (mild stimulant-type profile). Morning dosing plus a two-week sleep-latency log is the usual first check.

  • Nutrition: Indirect via possible sodium-dependent glucose-transporter absorption. Isolated human work did not require a special diet; empty-stomach or pre-training use is the extract custom.

  • Exercise: Potentiating for perceived effort and intermittent oxygen use in the isolated 60 mg trial. Common practice is 30–60 minutes before hard sessions, not as a substitute for Zone 2 (easy aerobic) or strength work.

  • Stress management: Extract data show a smaller morning cortisol rise and better burnout scores in some trials (indirect HPA (hypothalamic–pituitary–adrenal) effect). Isolated salidroside has no cortisol RCT.

Monitoring Protocol & Defining Success

Typical baseline capture before the first dose includes seated blood pressure on two mornings, a fasting glucose, a short sleep and mood log, and—if the goal is training—an interval or time-to-exhaustion mark. A baseline metabolic panel is common in anyone already on glucose or blood-pressure drugs, or in older adults. Isolated salidroside has no validated target biomarker; the table tracks change from the person’s own baseline plus functional ranges used in longevity practice.

Blood pressure and the sleep/mood log are commonly repeated at 1 week and 4 weeks, then every 3–6 months if the course continues. Fasting glucose is often rechecked at 4 weeks when diabetes drugs or a low baseline glucose are in play. The same training test is typically repeated at the end of a 2–4 week block. Insomnia, agitation, or symptomatic lightheadedness are usual reasons to pause.

Biomarker Optimal Functional Range Why Measure It? Context/Notes
Seated blood pressure 110–120 / 70–80 mmHg; watch change from own baseline Detects additive hypotension Morning, seated 5 min; conventional “normal” is <130/80 mmHg
Fasting glucose 75–85 mg/dL (4.2–4.7 mmol/L), or stable vs own baseline Detects extra glucose-lowering 8–12 h fast; conventional reference is typically 70–99 mg/dL
ALT Women <20–25 U/L; men <25–30 U/L if using high-dose extract Screens liver strain from multi-herb products ALT is alanine aminotransferase, a liver enzyme. Isolated salidroside has no hepatotoxicity signal; conventional labs often flag only >40 U/L
Morning salivary or serum cortisol Mid-lab range, or a flatter awakening rise vs own baseline Extract trials altered the awakening cortisol response Same clock time; not a dosing target for isolated salidroside
hs-CRP <0.7–1.0 mg/L, or down vs own baseline Optional inflammation context hs-CRP is high-sensitivity C-reactive protein, a general inflammation marker. Fasting preferred; conventional labs often flag only >3.0 mg/L; no isolated-salidroside target exists

Qualitative markers:

  • Sleep onset and next-day irritability
  • Perceived effort at a fixed workout
  • Afternoon mental stamina under load
  • Resting pulse and lightheadedness on standing

Emerging Research

  • Isolated exercise RCT follow-on: The 2024 60 mg/16-day trial is industry-linked and short. Independent replications with longer dosing, older adults, and pre-registered primary endpoints could raise or sink the exercise claim (Schwarz et al., 2024).

  • Ovarian aging / IVF (in vitro fertilization): NCT06990685 is a not-yet-recruiting Phase 2 open-label RCT (n=370, ages 35–39, poor ovarian response) of oral salidroside capsules versus no add-on, primary endpoint ongoing pregnancy.

  • HSP90 longevity mechanism: Direct HSP90 binding and invertebrate life extension (Zhang et al., 2024) will weaken the longevity case if human aging biomarkers do not move, or strengthen it if they do.

  • AMPK in fatty liver: Mouse NASH protection via AMPK (Hu et al., 2021) and the 2026 rodent NAFLD meta-analysis await a human metabolic trial—absence keeps the cardiometabolic claim speculative.

  • Negative or mixed extract literature: High-bias, conflicting Rhodiola fatigue reviews (Ishaque et al., 2012) remain a reason not to treat extract results as isolated-salidroside proof.

Conclusion

Salidroside is a defined plant phenol from Rhodiola roots, now also made by fermentation. For a health-optimizing adult, the human case for the isolated compound is still thin: one short trial in young exercisers reported better oxygen use in high-intensity intervals and a smaller rise in a muscle-damage marker, while mood, fatigue, and stress findings come mainly from mixed-root extracts that contain other actives. Laboratory work is broader, covering energy-sensing, antioxidant, and inflammatory pathways, plus longer life in simple animals and protection in models of memory loss, fatty liver, and kidney injury.

Risks look modest at studied isolated doses. Rat work set a high no-harm level, and enzyme-interaction tests did not flag major drug-metabolism problems for the pure compound at expected blood levels. Mixed extracts can cause dizziness, dry mouth, poor sleep, or irritability, and product identity is often unreliable. Some of the cleaner isolated-compound studies were funded by DoubleRainbow Biosciences and Lesaffre, makers of a bioengineered salidroside ingredient.

Overall evidence quality is laboratory-heavy for longevity claims and extract-heavy for day-to-day fatigue and mood. Isolated salidroside is a precise, relatively well tolerated tool with a still-limited human record.

Top - Benefits - Risks - Protocol